Moderate to Severe Plaque Psoriasis
Conditions
Brief summary
BCD-085 is an innovative drug, a monoclonal antibody against interleukin-17. The toxicity, safety, and pharmacokinetics of BCD-085 were investigated in animals, in phase I clinical study in healthy volunteers, and in phase III clinical study in patients with moderate to severe plaque psoriasis. This clinical study aims at investigating the efficacy and safety of BCD-085 every other week regimen (after induction for the first 3 weeks) versus BCD-085 one per month regimen (after induction for first 3 weeks) versus placebo in patients with moderate to severe plaque psoriasis. Study purpose: To investigate the efficacy and safety of BCD-085 versus placebo in patients with moderate to severe plaque psoriasis (psoriasis vulgaris) Study objectives: 1. To compare the efficacy of BCD-085 every 2 weeks versus BCD-085 every 4 weeks versus placebo, based on the proportion of patients who achieved a PASI75, target sPGA score, and on other secondary efficacy measures. 2. To evaluate the proportion of patients in each study arm who develop adverse events with multiple injections of BCD-085 and placebo. Compare the safety profiles of BCD-085 when used every 4 weeks and when used every 2 weeks. 3. 4\. To assess the immunogenicity of BCD-085 defined as the proportion of patients who develop anti-drug antibodies (binding or neutralizing).
Interventions
DRUGBCD-085 Q2W
In Arm 1, the test drug BCD-085 will be used at a dose of 120 mg given as two SC injections according to the following schedule: once a week for the first 3 weeks (induction treatment) and then once every 2 weeks through Week 10. On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label patients will receive BCD-085 through week 50. The follow-up will continue through week 54.
DRUGBCD-085 Q4W
In Arm 2, and then once every 4 weeks through Week 10. On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 2 will be given BCD-085 once every 4 weeks through week 50. The follow-up will continue through week 54.
DRUGPlacebo
In Arm 3, patients will be given two SC injections of placebo (1.0 mL each) according to the following schedule: on Day 1 of weeks 0, 1, 2 and then once every 2 weeks through Week 10. On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 3 will receive BCD-085 at weeks 12, 13, 14 and then once every 4 weeks through week 50. The follow-up will continue through week 54.
Sponsors
Biocad
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Subjects must give a written and signed informed consent. 2. Men or women at least 18 years old at the time of signing the ICF 3. Moderate to severe plaque psoriasis diagnosed at least 6 months before signing the informed consent form. 4. Patients received at least one course of phototherapy or systemic therapy for psoriasis or are candidates for such treatment according to the investigator. 5. Body surface area (BSA) affected by psoriasis of 10% or greater, the PASI score of 10 or greater, and the sPGA score of 3 or greater at screening. 6. Negative pregnancy urine test in female subjects (no test is required in women who are post-menopausal for at least 2 years and in surgically sterile women). 7. The patient must be able to follow the Protocol procedures (in the investigator's opinion). 8. Patients of childbearing potential and their partners with preserved reproductive function must implement reliable contraceptive methods starting from signing informed consent to 20 weeks after the last dose of the study therapy. This requirement does not apply to the patients after surgical sterilization and to females who are post-menopausal for 2 years or longer. Reliable contraception methods suggest using one barrier method in combination with one of the following: spermicides, intrauterine device/oral contraceptives
Exclusion criteria
1. Baseline erythrodermic, pustular, and guttate psoriasis or any other skin diseases (e.g. eczema) that can affect/complicate assessment of psoriasis treatment 2. Use of the following medications: * Prior use of monoclonal antibodies targeting IL17 or its receptor * Prior use of more than one drug containing monoclonal antibodies or their fragments * Prior use of monoclonal antibodies within 12 weeks before signing the informed consent. * Any systemic medications for psoriasis (including glucocorticoids, methotrexate, sulfasalazine, cyclosporine, acitretin, mycophenolate mofetil, аpremilast, calcitriol derivatives, etc.) used within 4 weeks before signing the ICF If prior systemic therapy with non-biologics was stopped due to any reasons, the screening period can be extended up to 8 weeks during which no new non-biologics are allowed. * Use of phototherapy within 4 weeks before signing the ICF * Topical medications for psoriasis used within 2 weeks before signing the ICF * Vaccination with live or attenuated vaccines within 8 weeks before signing the ICF 3. Any active systemic infection or recurrent infection at screening/randomization 4. HIV, hepatitis B, hepatitis C, or syphilis 5. Blood biochemistry abnormalities appearing as: 1. baseline creatinine \> 2 × ULN 2. baseline ALT, AST or alkaline phosphatase \> 2.5 × ULN 3. baseline bilirubin \> 1.5 × ULN 6. WBC count \< 3.0 × 109/L; ANC \< \<2.0× 109/L; platelet count \< 100 × 109/L, or hemoglobin \< 90 g/L at baseline 7. Any psychiatric conditions including severe depressive disorders and/or any history of suicidal thoughts or suicidal attempts ; 8. Signs of clinically significant depression (Beck's score of 16 or more at screening) 9. Alcohol or substance abuse 10. Tuberculosis now or in the past 11. Latent TB infection (positive results of the Diaskintest or QuantiFERON test, or T-spot). 12. Concurrent diseases ongoing at screening that may increase the risk of adverse events during the study or affect the evaluation of psoriasis symptoms (mask, enhance or alter the symptoms of psoriasis, or cause clinical or laboratory signs/symptoms similar to those of psoriasis): * active inflammatory diseases or aggravation of chronic inflammatory diseases other than psoriasis * Stable angina class III-IV, unstable angina or a history of myocardial infarction within 1 year before signing the informed consent * Cardiac failure moderate to severe (NYHA class III-IV) * Treatment-resistant hypertension * A history of severe asthma or angioedema * Moderate to severe respiratory failure, COPD grade ¾ * Diabetes mellitus with unsatisfactory glycemic control, when the level of glycated hemoglobin HbA1С ≥8% (results are valid if the test was performed at the screening or within 3 months before signing the ICF) * The patient has thyrotoxicosis, which persists in the presence of thyreostatic medications, or hypothyroidism despite of the thyroid hormone treatment * Systemic autoimmune diseases (including but not limited to SLE, rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, systemic scleroderma, inflammatory myopathy, mixed connective tissue disease , intersection syndrome, etc.) * Any other underlying conditions (including but not limited to metabolic, hematologic, hepatic, renal, pulmonary, neurological, endocrine, cardiac, gastrointestinal conditions and infections) that, in the opinion of the investigator, may affect the course of psoriasis, affect the assessment of signs/symptoms of psoriasis, or put patients using the study treatment at additional risk 13. Malignancies with less than 5 years of remission 14. Known severe allergies (anaphylaxis or drug allergy to two or more drug products) 15. Known allergy or intolerance to monoclonal antibody drugs (murine, chimeric, humanized, or human) or any other components of the test drug or comparator 16. Major surgery within 30 days before the screening, or a major surgery being scheduled at any time during the study 17. Severe infections (including those that required hospitalization or parenteral antibacterial/antimycotic/antiprotozoal treatment) within 6 months before signing the ICF 18. Systemic antibacterial/antimycotic/antiprotozoal treatment within 2 months before the signing the ICF 19. More than 4 episodes of respiratory infection within 6 months before signing the ICF 20. Episodes of severe mycoses (histoplasmosis, coccidioidomycosis, blastomycosis, etc.) within 6 months before signing the ICF 21. A history of epileptic attacks or seizures 22. Any concurrent diseases during which, in the investigator's opinion, the study treatment can harm the patient 23. Pregnancy, breastfeeding, or planning for pregnancy while participating in the study 24. Participation in any other clinical study within 3 months before signing the ICF or simultaneous participation in other clinical studies 25. Patients will not be re-enrolled in this study if they were randomized to this study and then discontinue the participation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| • The Proportion (Number) of Patients in Each Study Arm Who Achieved a PASI 75 at Week 12 of Treatment | week 12 | The Psoriasis Area and Severity Index (PASI) allows evaluating the extent and severity of skin symptoms of psoriasis. Body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself and scores are combined for final PASI: 0 (no disease) to 72 (maximal disease). Relative (percentage) change in PASI score from baseline (screening) is calculated as 100 x (baseline value - time point t value) / (baseline value) PASI 75 indicates a 75% or greater reduction in PASI scores from baseline and is indicative of excellent disease improvement. |
Countries
Russia
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| BCD-085 Q2W Patients in this arm (85 subjects) will receive 120 mg BCD-085 (two SC injections, 60 mg in 1.0 mL each). Thus, the drug will be administered on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2 (induction), Day 1 of Week 4, Day 1 of Week 6, Day 1 of Week 8, and Day 1 of Week 10.
On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 1 will be given BCD-085 every 4 weeks through Week 50.
BCD-085 Q2W: In Arm 1, the test drug BCD-085 will be used at a dose of 120 mg given as two SC injections according to the following schedule: once a week for the first 3 weeks (induction treatment) and then once every 2 weeks through Week 10.
On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label patients will receive BCD-085 through week 50. The follow-up will continue through week 54. | 85 |
| BCD-085 Q4W Patients in this arm (85 subjects) will receive 120 mg BCD-085 (two SC injections, 60 mg in 1.0 mL each). Thus, the drug will be administered on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2 (induction), Day 1 of Week 6 and Day 1 of Week 10. For the purpose of blind design, patients will receive a placebo (2 injections) on day 1 of week 4 and week 8.
On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 2 will continue BCD-085 every 4 weeks through Week 50.
BCD-085 Q4W: In Arm 2, and then once every 4 weeks through Week 10. On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 2 will be given BCD-085 once every 4 weeks through week 50. The follow-up will continue through week 54. | 84 |
| Placebo Patients in this arm (43 subjects) will be given two SC injections of placebo (1.0 mL each) on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2, Day 1 of Week 4, Day 1 of Week 6, Day 1 of Week 8, and Day 1 of Week 10.
On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 3 will receive BCD-085 on Day 1 of Week 12, Day 1 of Week 13, Day 1 of Week 14 (induction), then every 4 weeks through Week 50.
Placebo: In Arm 3, patients will be given two SC injections of placebo (1.0 mL each) according to the following schedule: on Day 1 of weeks 0, 1, 2 and then once every 2 weeks through Week 10.
On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 3 will receive BCD-085 at weeks 12, 13, 14 and then once every 4 weeks through week 50. The follow-up will continue through week 54. | 44 |
| Total | 213 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Weeks 0-12 | Lost to Follow-up | 0 | 1 | 0 |
| Weeks 0-12 | Withdrawal by Subject | 0 | 1 | 1 |
| Weeks 12-54 | Adverse Event | 2 | 1 | 1 |
| Weeks 12-54 | Pregnancy | 1 | 0 | 0 |
| Weeks 12-54 | Withdrawal by Subject | 0 | 3 | 1 |
Baseline characteristics
| Characteristic | BCD-085 Q4W | Total | BCD-085 Q2W | Placebo |
|---|---|---|---|---|
| Age, Continuous | 41.5 years | 42 years | 42 years | 39 years |
| Body Surface Area Affected by Psoriasis (BSA) | 22 percentage of BSA | 22 percentage of BSA | 20 percentage of BSA | 22.5 percentage of BSA |
| Height | 176 cm | 176 cm | 178 cm | 175.5 cm |
| PASI score | 17.9 score | 18.6 score | 18.4 score | 19.7 score |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 84 Participants | 213 Participants | 85 Participants | 44 Participants |
| Sex: Female, Male Female | 26 Participants | 57 Participants | 22 Participants | 9 Participants |
| Sex: Female, Male Male | 58 Participants | 156 Participants | 63 Participants | 35 Participants |
| sPGA score | 4 score | 3 score | 3 score | 4 score |
| Weight | 89.5 kg | 87.3 kg | 87.3 kg | 83.5 kg |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 85 | 0 / 84 | 0 / 44 |
| other Total, other adverse events | 15 / 85 | 13 / 84 | 8 / 44 |
| serious Total, serious adverse events | 0 / 85 | 1 / 84 | 0 / 44 |
Outcome results
Primary
• The Proportion (Number) of Patients in Each Study Arm Who Achieved a PASI 75 at Week 12 of Treatment
The Psoriasis Area and Severity Index (PASI) allows evaluating the extent and severity of skin symptoms of psoriasis. Body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself and scores are combined for final PASI: 0 (no disease) to 72 (maximal disease). Relative (percentage) change in PASI score from baseline (screening) is calculated as 100 x (baseline value - time point t value) / (baseline value) PASI 75 indicates a 75% or greater reduction in PASI scores from baseline and is indicative of excellent disease improvement.
Time frame: week 12
Population: ITT-population (all randomized)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| BCD-085 Q2W | • The Proportion (Number) of Patients in Each Study Arm Who Achieved a PASI 75 at Week 12 of Treatment | 66 Participants |
| BCD-085 Q4W | • The Proportion (Number) of Patients in Each Study Arm Who Achieved a PASI 75 at Week 12 of Treatment | 70 Participants |
| Placebo | • The Proportion (Number) of Patients in Each Study Arm Who Achieved a PASI 75 at Week 12 of Treatment | 0 Participants |